Callan JMB to Participate in Upcoming March Conferences
- SPRING BRANCH, Texas, March 13, 2025 (GLOBE NEWSWIRE) -- Callan JMB INC. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency management agencies through exceptional fulfillment, storage, monitoring, and cold chain logistics services, today announced that management will participate in the following March 2025 investor conferences.
- 03/13/2025
|
Callan JMB Unveils Innovative Immunization Management Infrastructure Lease Program for Government Agencies and Private Organizations
- SPRING BRANCH, Texas, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Callan JMB INC. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency management agencies through exceptional fulfillment, storage, monitoring, and cold chain logistics services, today announced a new comprehensive lease program for vaccine management that will enable government agencies and private organizations to provide crucial immunizations without the economic burden of purchasing the necessary equipment outright.
- 02/28/2025
|
Callan JMB Announces Partial Exercise of Underwriters' Over-Allotment Option in Connection with its Initial Public Offering
- SPRING BRANCH, Texas, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Callan JMB Inc. (NASDAQ: CJMB) (“Callan” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency management agencies through exceptional fulfillment, storage, monitoring, and cold chain logistics services, today announced that the underwriters of its previously announced initial public offering of shares of its common stock (“Common Stock”) have partially exercised their over-allotment option, resulting in the issuance of an additional 163,569 shares of Common Stock (the “Option Shares” or “Share”) at a public offering price of $4.00 per Share for additional gross proceeds of $654,276. After giving effect to the partial exercise of the over-allotment option, an aggregate of 1,443,569 shares of Common Stock have been issued in the initial public offering (the “Offering”) for aggregate net proceeds of approximately $4,729,319.78, after deducting underwriting discounts, commissions and offering expenses payable by the Company.
- 02/07/2025
|
Callan JMB Announces Closing of $5.12 Million Initial Public Offering
- SPRING BRANCH, Texas, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Callan JMB Inc. (NASDAQ: CJMB) (“Callan” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency management agencies through exceptional fulfillment, storage, monitoring, and cold chain logistics services, today announced the closing of its previously announced initial public offering (the “Offering”) of 1,280,000 shares (the “Shares”) of common stock (“Common Stock”) at an initial public offering price of $4.00 per Share for a total of approximately $5,120,000 of gross proceeds to the Company before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. In addition, Callan has granted the underwriters a 45-day option to purchase, at the public offering price, up to an additional 192,000 shares of Common Stock at the public offering price, less the underwriting discounts and commissions.
- 02/06/2025
|
Callan JMB Announces Pricing of $5.12 Million Initial Public Offering
- SPRING BRANCH, Texas, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Callan JMB Inc. (NASDAQ: CJMB) (“Callan” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency management agencies through exceptional fulfillment, storage, monitoring, and cold chain logistics services, today announced the pricing of its initial public offering (the “Offering”) of 1,280,000 shares (the “Shares”) of common stock (“Common Stock”) at an initial public offering price of $4.00 per Share for a total of approximately $5,120,000 of gross proceeds to the Company before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. In addition, Callan has granted the underwriters a 45-day option to purchase, at the public offering price, up to an additional 192,000 shares of Common Stock at the public offering price, less the underwriting discounts and commissions.
- 02/04/2025
|